Tevimbra regimen cleared for first-line HER2+ gastroesophageal adenocarcinoma

What this means

Tevimbra is an immune-boosting cancer drug that helps the body's defenses attack tumors by blocking the PD-1 protein. The FDA has now approved its use, in combination with other medicines, as an initial treatment for patients with HER2-positive gastroesophageal adenocarcinoma. This expands the first-line options for this specific type of stomach and esophageal cancer.